Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs DOI Creative Commons

Phannicha Kosukwatthana,

Oumaporn Rungsuriyawiboon, Jatuporn Rattanasrisomporn

и другие.

Animals, Год журнала: 2024, Номер 14(24), С. 3683 - 3683

Опубликована: Дек. 20, 2024

Cannabidiol, the primary non-psychoactive phytocannabinoid found in cannabis, has generated significant research interest due to its potential for biological effects, such as anti-inflammatory, analgesic, immunomodulatory, and anticonvulsant properties. Several studies have demonstrated of CBD alter inflammatory cytokines; however, data on CBD’s effects cell viability pro-inflammatory cytokines target animals, dogs, are limited. Therefore, this study, we investigated modulation cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), canine PBMCs stimulated with LPS. To evaluate effect neuroinflammation epilepsy pathology, an independent study five refractory epileptic dogs co-treated 30 days was conducted. The current findings revealed that concentrations 16 µg/mL had a statistically calculated IC50 15.54 µg/mL. LPS-stimulated tended be dose-dependent, 5–30 μg/mL resulting decreased production tested cytokines. Considering cytokine by from modulate immune responses provide benefits when used combination antiepileptic drugs. provided evidence cytotoxicity alteration PBMCs.

Язык: Английский

A Preliminary Evaluation of the Comparative Efficacy of Gel-Based and Oil-Based CBD on Hematologic and Biochemical Responses in Dogs DOI Creative Commons

Wassana Puttharaksa,

Rangsun Charoensook,

Rongdej Tungtrakanpoung

и другие.

Veterinary Sciences, Год журнала: 2025, Номер 12(4), С. 342 - 342

Опубликована: Апрель 7, 2025

Cannabidiol (CBD) has gained popularity in veterinary medicine for its potential to alleviate stress, pain, and inflammation dogs. However, oral administration is limited by hydrophobicity, variable absorption, extensive first-pass metabolism, which requires optimized delivery methods enhance efficacy. This study investigated the effects of daily supplementation CBD oil gel (each at 4 mg/kg), compared a placebo, over 14 days shelter dogs subjected solitary confinement-induced stress. Both formulations appeared safe under conditions, with no adverse on hematological biochemical parameters. Post-stress cortisol levels were significantly lower CBD-treated groups controls, CBD-infused showing pattern toward greater attenuation. Multivariate analysis revealed distinct blood profile shifts dogs, PCA loadings indicating associations between lymphocyte percentages IgG levels. These findings support gel-based as promising strategy stress modulation Further studies should explore pharmacokinetics long-term immune optimize applications.

Язык: Английский

Процитировано

1
The Potential of Cannabidiol for Treating Canine Atopic Dermatitis DOI Creative Commons
Ana Filipa Bizarro Camões, Vanessa Schmidt, Beatriz Fernandes

и другие.

Veterinary Sciences, Год журнала: 2025, Номер 12(2), С. 159 - 159

Опубликована: Фев. 12, 2025

Atopic dermatitis is prevalent in humans (hAD) and dogs (cAD) profoundly impacts the patients’ quality of life. The increasing number new drugs development for atopic indicates both need potential precision medicine to generate an optimised benefit–risk therapeutic plan. Cannabidiol (CBD), known its anti-inflammatory antipruritic properties, shows promise hAD cAD management, prompting exploration cannabinoids (CBs) CBD as tools. In fact, encouraging results on benefits using have been published, along with safety evaluations that reveal generally well tolerated dogs. However, limited placebo-controlled trials dosage variations pose barriers hinder definitive conclusions. Challenges product stability, inconsistent formulations, legal ambiguities highlight standardised CBD-based products research commercial uses. complex landscape further complicates accessibility regulation. Despite these challenges, emerging a avenue urging high-quality research, clarity. This brief review provides valuable insights into CBs cAD, compared hAD, emphasising importance rigorous unambiguous regulation successful integration veterinary dermatology.

Язык: Английский

Процитировано

0
Pharmacokinetics of Non-Psychotropic Phytocannabinoids DOI Creative Commons

Mariana Lacerda,

Andreia Carona,

Sara Castanheira

и другие.

Pharmaceutics, Год журнала: 2025, Номер 17(2), С. 236 - 236

Опубликована: Фев. 12, 2025

Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates medical research applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC), along with corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic (CBGA), Cannabichromenic (CBCA). Among these cannabinoids, CBD is most extensively studied. Nevertheless, involving all mentioned cannabinoids has shown that pharmacokinetic parameters highly variable, depending significantly on factors such as dose, formulation, route administration, diet. Furthermore, challenges brain penetration first-pass metabolism have been highlighted. In conclusion, this demonstrates progress in understanding non-psychotropic cannabinoids. However, it also underscores need further research, particularly CBG, CBC, respective gap being clinical investigations. Expanding studies essential facilitate optimized use treatments.

Язык: Английский

Процитировано

0
Pharmacokinetics of a single oral administration of two cannabidiol formulations in fed and fasted horses DOI Creative Commons
Alessandra Di Salvo, Marilena Bazzano, Giorgia Della Rocca

и другие.

Frontiers in Veterinary Science, Год журнала: 2025, Номер 12

Опубликована: Фев. 19, 2025

Pain management in horses plays a pivotal role the therapeutic approach to several diseases. Horses have cannabinoid receptors at level of dorsal root ganglia, blood vessels, and synoviocytes that can be up or down- regulated by inflammatory conditions, justifying possible efficacy exogenous cannabinoids (i.e., phytocannabinoids) managing painful pathologies this animal species. However, current use supplements containing cannabidiol (CBD) equines is based on anecdotal evidence, without support sufficient pharmacokinetic studies. In humans, concentration peak CBD area under concentration-time curve (AUC) are both strongly influenced food administration. Also, equids, oral bioavailability some drugs meal but no information available about CBD. This study investigated pharmacokinetics following single administration two different formulations pure (oil paste), dosed 1 mg/kg, times oil paste were administered orally mg/kg eight healthy according cross over design, samples taken pre-fixed time-points for analyses. The obtained data did not allow statistically significant differences between (paste oil) feeding time (fed fasted status). treatment with paste, Cmax was achieved shorter range compared oily formulation, indicating it could better formulation consider future equine

Язык: Английский

Процитировано

0
Pharmacokinetic Characteristics of a Single Cannabidiol Dose in Oil and Treat Forms and Health Impacts After 30 Days of Administration in Dogs DOI Creative Commons

Phattharakan Kamutchat,

Sasithorn Limsuwan,

Nattaya Leewichit

и другие.

Animals, Год журнала: 2025, Номер 15(10), С. 1470 - 1470

Опубликована: Май 19, 2025

Cannabidiol (CBD) has garnered significant interest in veterinary therapeutics, yet the pharmacokinetic and safety profiles of its various formulations remain incompletely characterized. This study compared pharmacokinetics (PK) health effects CBD administered as oil (OG, 5 mg/kg) treats (TG, 50 mg) 16 healthy mixed-breed dogs over 30 days. Plasma concentrations were measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS), PK parameters analyzed non-compartmental methods. The CBD-infused rice bran formulation (OG) achieved a significantly higher dose-normalized maximum plasma concentration (Cmax, 58.40 vs. 21.29 kg·ng/mL/mg) area under curve (AUC0-inf, 305.85 141.75 h·kg·ng/mL/mg) to (TG). treat exhibited relative reductions bioavailability, with AUC Cmax values approximately 2.2- 2.7-fold lower than group. terminal half-life (~9.66 h OG 8.52 TG) time peak (2.38 3.63 did not differ significantly. accumulation occurred repeated dosing but declined rapidly post-cessation. hematological biochemical analyses revealed no clinically adverse effects, though minor erythrocyte eosinophil fluctuations noted. demonstrated superior absorption, while both forms well-tolerated. These findings highlight impact on absorption support further research into optimized delivery methods for applications.

Язык: Английский

Процитировано

0
The Potential of Cannabidiol in the Management of Oral Infections DOI Creative Commons
María Pía Ferraz

Applied Sciences, Год журнала: 2025, Номер 15(10), С. 5736 - 5736

Опубликована: Май 20, 2025

Oral infections, caused by bacterial, fungal, and viral pathogens, are a significant source of dental morbidity can lead to systemic complications, especially in immunocompromised individuals. Complex microbial interactions host immune responses drive common conditions such as caries, periodontal disease, oral candidiasis, herpetic lesions. Conventional antimicrobial therapies face limitations due resistance adverse effects, prompting interest alternative treatments. Cannabidiol (CBD), non-psychoactive compound derived from Cannabis sativa, has emerged promising candidate its antimicrobial, anti-inflammatory, immunomodulatory properties. CBD targets various molecular pathways, including cannabinoid receptors, TRP channels, adenosine PPARs, contributing multifaceted therapeutic effects. It demonstrated efficacy against pathogens Streptococcus mutans, Enterococcus faecalis, Candida albicans, disrupting biofilms bacterial membranes. Additionally, modulates inflammatory reducing cytokine production oxidative stress, particularly relevant chronic like disease. Emerging evidence also suggests synergistic effects with conventional antimicrobials benefits tissue regeneration. This review highlights the potential managing offering novel approach overcoming current treatment guiding future research into safer more effective health interventions.

Язык: Английский

Процитировано

0
Cannabidiol as an immune modulator: A comprehensive review DOI Creative Commons

Khizra Mujahid,

Muhammad Rasheed,

Azka Sabir

и другие.

Saudi Pharmaceutical Journal, Год журнала: 2025, Номер 33(3)

Опубликована: Май 23, 2025

Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has emerged as promising therapeutic agent due to its diverse pharmacological properties, including potent anti-inflammatory, neuroprotective, and immunomodulatory effects. CBD modulates immune responses, the regulation of T cell activity, induction macrophage apoptosis, suppression pro-inflammatory cytokines, modulation signaling pathways involved in inflammation homeostasis. A comprehensive literature search was conducted using PubMed, Scopus, Web Science databases identify relevant preclinical clinical studies on CBD's Preclinical demonstrate efficacy treating autoimmune diseases such Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, along with potential neuropathic pain cancer therapy. Recent advancements nanotechnology-based delivery systems have further enhanced by improving solubility, bioavailability, targeted delivery, enabling innovative approaches for wound healing, management, treatment. However, challenges variability limited long-term safety data, drug-drug interactions persist. This review comprehensively examines pharmacokinetics, pharmacodynamics, mechanisms, highlighting potential, existing limitations, future directions advancing integration into precision medicine regulation.

Язык: Английский

Процитировано

0
Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review DOI Creative Commons
Alessandra Di Salvo, Elisabetta Chiaradia, Monica Sforna

и другие.

Veterinary Research Communications, Год журнала: 2024, Номер 48(5), С. 2915 - 2941

Опубликована: Авг. 20, 2024

Since the discovery of endocannabinoid system and due to empirical evidence therapeutic effects on several illnesses both in humans animals that follow administration exogenous cannabinoids (i.e., phytocannabinoids), numerous studies have been conducted. These investigations aimed identify expression distribution cannabinoid receptors healthy pathologic organs tissues different animal species define interactions phytocannabinoids with these receptors. In last decade, pharmacokinetics, efficacy tolerability many Cannabis derivatives formulations, mainly containing cannabidiol, main veterinary interest, also investigated. This manuscript summarizes findings reported by scientific published so far molecular mode action phytocannabinoids, localization tissues, as well dogs, cats, horses other interest. A deep knowledge issues is crucial for use purposes species.

Язык: Английский

Процитировано

2
Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs DOI Creative Commons

Phannicha Kosukwatthana,

Oumaporn Rungsuriyawiboon, Jatuporn Rattanasrisomporn

и другие.

Animals, Год журнала: 2024, Номер 14(24), С. 3683 - 3683

Опубликована: Дек. 20, 2024

Cannabidiol, the primary non-psychoactive phytocannabinoid found in cannabis, has generated significant research interest due to its potential for biological effects, such as anti-inflammatory, analgesic, immunomodulatory, and anticonvulsant properties. Several studies have demonstrated of CBD alter inflammatory cytokines; however, data on CBD’s effects cell viability pro-inflammatory cytokines target animals, dogs, are limited. Therefore, this study, we investigated modulation cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor-α (TNF-α), canine PBMCs stimulated with LPS. To evaluate effect neuroinflammation epilepsy pathology, an independent study five refractory epileptic dogs co-treated 30 days was conducted. The current findings revealed that concentrations 16 µg/mL had a statistically calculated IC50 15.54 µg/mL. LPS-stimulated tended be dose-dependent, 5–30 μg/mL resulting decreased production tested cytokines. Considering cytokine by from modulate immune responses provide benefits when used combination antiepileptic drugs. provided evidence cytotoxicity alteration PBMCs.

Язык: Английский

Процитировано

2